You built the instrument. We’ll build the business that sells it.
For technical founders and C-level teams, pre-seed to Series B, with small, limited, or no commercial team.
Focus on the science, we’ll take it to market.
35+ years and 25+ launches, working from day one. No twelve-month build, no equity grant, no bad hire to unwind.
A network of 30,000+ scientists, KOLs, and industry leaders across drug discovery, diagnostics, CGT, and personalized medicine. We connect you with the people who decide whether your technology gets adopted.
Global manufacturing and supply chain networks across the Americas, EU, and Asia. We help turn early production into a reliable, scalable operation that can support commercial demand.
Companies we’ve worked with have raised $150M+. At pre-seed to Series B, commercial traction is what the term sheet is built on.
We scaled the iQue platform from a niche screening tool into a system installed at the top 15 global pharmaceutical companies, and delivered a cash exit at a multiple well above life-science tools norms.
Breakthrough science, no product, no commercial organization. We took VisionSort from design to manufacturing release in nine months, launched at SLAS 2023, and stood up a 30-person global commercial organization in the first year.
Scaling a hardware-plus-AI platform out of Japan into the US and EU needed capital that pure venture equity could not supply. We blended institutional venture, strategic corporate investors, and Japanese government non-dilutive funding, bringing total funding to $91M while limiting dilution.
ForteBio entered a market owned by Biacore’s slow, expensive SPR systems. Positioning Bio-Layer Interferometry as the faster alternative, we launched the Octet platform and a biosensor consumables line that reached 11 products, creating the recurring-revenue engine that became the anchor of Pall’s acquisition, today part of Sartorius.
No handoffs between specialists. No disappearing between phases.
Define the market, the buyer, the commercial model, and the milestone-based roadmap. Translate your science into the right path to revenue.
Launch planning, pricing, reimbursement, channel strategy, and field readiness. Everything that turns a cleared product into commercial scale.
Identify, evaluate, and negotiate partnerships, licensing deals, and collaborations that expand capabilities and unlock strategic growth.
Global manufacturing networks, CMO/CDMO selection, scale-up readiness, and distribution partnerships across the Americas, EU, and Asia.
Microbioreactors and nanoparticle analysis platforms we have commercialized for the technology developers behind them.
Accelerate Cell Line Development by 29 to 42 percent with true dynamic mixing at 24- and 96-well scale. Real-time DO and pH metabolic insight at the microplate stage.
Request DetailsSee metabolism in motion. Continuously monitor DO, pH, OCR, and ECAR in real time for full-course metabolic profiling throughout the entire culture period.
Request DetailsThree founders with decades of senior leadership across pharma, biotech, and diagnostics, backed by specialists across every commercial function and an advisory board of industry-leading experts.
Strategy, commercialization, and capital. Multi-product launches across pharma and life science tools.
Operations, manufacturing, and global distribution. Decades scaling life science companies through launch and beyond.
Licensing, partnerships, and business development across biotech, diagnostics, and life science tools.
A 12-point self-assessment built from 20+ life science launches. Use it to evaluate whether your product is ready for commercial launch.
